Platform biotech with three recent approvals now bets its next leg of growth on a functional hepatitis B cure — if FDA agrees the B-Well data support approval

Ionis is a commercial-stage biotech company with three recently approved rare disease drugs that is now seeking approval for an unapproved treatment for chronic hepatitis B.

Ionis has won three U.S. approvals in roughly a year, DAWNZERA, TRYNGOLZA, and ZANVASTRO, reshaping it from a royalty-dependent licensor into a commercial-stage rare disease company. Bepirovirsen, a BTD-designated antisense oligonucleotide targeting chronic hepatitis B functional cure, carries the highest near-term value inflection, with Phase 3 B-Well 1 and B-Well 2 both meeting statistical significance. The key risk is regulatory: functional cure endpoints remain novel, and FDA scrutiny of what constitutes a clinically meaningful bar could produce a complete response letter even against positive Phase 3 data.